Bacil Pharma Outlines Expansion and Leadership Restructuring at 39th AGM

Authorized Capital Expansion: Rs 70 Crore
Management: Appointment of Ms. Chaitali Kalpataru Shah as MD

Reader Takeaway: Capital expansion provides future funding flexibility, while leadership changes signal a new phase of strategic governance.

What just happened

Bacil Pharma Ltd has issued a formal notice for its 39th Annual General Meeting, scheduled for September 23, 2026. The meeting will be conducted entirely via video conferencing, with no physical venue. The board has proposed several structural changes, most notably an increase in the company's authorized share capital from Rs 20 crore to Rs 70 crore. This move aims to expand the capital base by authorizing the issuance of up to 70 million equity shares of Rs 10 each.

Leadership and Board Changes

Effective August 25, 2026, Ms. Chaitali Kalpataru Shah has been designated as the Managing Director of the firm. Her tenure is set to run until July 28, 2029. Additionally, shareholders will vote on the regularization of four new directors: Mr. Omprakash Pyarelal Sonar, Mr. Vivek Mukesh Yadav, Mr. Mahesh Singh, and Mr. Anil Singh, who were previously appointed as Additional Directors.

Auditor Appointment

In accordance with regulatory norms, the company has proposed the appointment of M/s Sarang Shivajirao Chavan & Associates as statutory auditors for a five-year term. This appointment will span from the conclusion of the upcoming 39th AGM until the conclusion of the 43rd AGM.

What changes now

The increase in authorized capital provides Bacil Pharma with the necessary regulatory headroom for potential future equity issuance or capital raising activities. While no immediate fundraising plans have been disclosed, this amendment to the Memorandum of Association simplifies future corporate actions. Shareholders are now invited to vote on these proposals, which are vital to the firm's evolving governance and expansion strategy.